Breaking News

Almac, PILA PHARMA Enter API Manufacturing Pact

Almac will manufacture XEN-D0501, a highly selective and very potent small molecule TRPV1 antagonist for ongoing type 2 diabetes clinical studies.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Almac Sciences, a global provider of drug development services and member of the Almac Group, has signed a manufacturing agreement with Swedish biotech company, PILA PHARMA, for the production of XEN-D0501 active pharmaceutical ingredient (API).   Almac Sciences will manufacture XEN-D0501, a highly selective and very potent small molecule TRPV1 antagonist, from its global headquarters in Northern Ireland. The TRPV1 target was previously in development by Bayer and Xention/Ario Pharma and has d...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters